復星醫藥(02196.HK):預計Gland Pharma將於印度時間11月20日在孟交所及印交所上市
格隆匯11月13日丨復星醫藥(02196.HK)公佈,公司控股子公司Gland Pharma已於印度標準時間2020年11月12日向印度的公司註冊處遞交日期為2020年11月12日的正式招股書,並於印度標準時間2020年11月13日向印度證券交易委員會、孟買證交所及印度證交所遞交招股書。
根據招股書,待確定配股基準後,該次Gland Pharma境外上市將公開發售共計4319.6968萬股股份,其中:(1)以新股發行方式公開發售833.3333萬股股份,(2)以現有股東發售股份)方式公開發售3486.3635萬股股份(包括公司控股子公司Fosun Pharma Industrial Pte. Ltd.出售1936.8686萬股股份、其他現有股東出售合計1549.4949萬股股份)。上述股份的最終發售價格均為1500印度盧比/股。
預計Gland Pharma境外上市公開發售的股份將於印度標準時間2020年11月19日(星期四)分配至承配人賬户。如獲孟買證交所及印度證交所最終上市及交易核准,預計Gland Pharma股份將於印度標準時間2020年11月20日(星期五)在孟買證交所及印度證交所開始買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.